|
Age, median (range), year
|
62 (17–85)
|
62 (23–80)
|
0.558
|
|
Gender, male:female, n (%)
|
120:61 (66:34)
|
7:7 (50:50)
|
0.250
|
|
WHO/FAB classification, n (%)
| | |
0.891
|
|
RCMD
|
47 (26.0)
|
3 (21.4)
| |
|
RAEB-1
|
57 (31.5)
|
3 (21.4)
| |
|
RAEB-2
|
39 (21.5)
|
5 (35.7)
| |
|
RAEB-t
|
12 (6.6)
|
1 (7.1)
| |
|
CMML-1
|
17 (9.4)
|
1 (7.1)
| |
|
CMML-2
|
9 (5.0)
|
1 (7.1)
| |
|
IPSS risk, n (%)
| | |
0.858
|
|
Intermediate-1
|
84 (46.4)
|
7 (50.0)
| |
|
Intermediate-2
|
77 (42.5)
|
5 (35.7)
| |
|
High
|
20 (11.1)
|
2 (14.3)
| |
|
Cytogenetic risk group, n (%)
| | | |
|
Good
|
108 (59.7)
|
12 (85.7)
|
0.072
|
|
Intermediate
|
31 (17.1)
|
2 (14.3)
| |
|
Poor
|
42 (23.2)
|
0
| |
|
Decitabine cycles, median (range), n
|
4 (1–11)
|
4 (2–7)
|
0.411
|
